Latest Immunotherapy Treatments

A Vaccine to Prevent and Treat Mesothelioma Could be Possible in the Future

A vaccine for lung cancer could possibly lead to a vaccine for mesothelioma. The lung cancer immunotherapy drug CIMAvax-EFG is making great progress, and because of this progress, researchers are utilizing the treatment in new ways. The researchers are trying to see how the vaccine can be used to prevent[…]

Read More »

Cytokine Factories to Treat Pleural and Peritoneal Mesothelioma

A new study from Rice University in Houston is showing promising results for mesothelioma. It utilizes the immune system to fight cancer cells. The protein that is being studied is interleukin 2 (IL2), which is a protein that regulates white blood cells through the use of cytokines, a cell signal[…]

Read More »

Opdivo and Yervoy After Mesothelioma Surgery Improves Survival

There might be more options for treating mesothelioma. A study looked at the combination of Opdivo and Yervoy after surgery. The study was performed at the Hyogo College of Medicine in Japan. Opdivo and Yervoy, which were recently approved for the treatment of mesothelioma, improved survival when administered after surgery.[…]

Read More »

A Treatment Involving Checkpoint Inhibitors Before Surgery is Showing Promising Results for Mesothelioma

Immunotherapy before aggressive surgery shows great promise for pleural mesothelioma. The combination has shown that it can improve survival for a group of patients with pleural mesothelioma in a phase II study at Baylor College of Medicine. The treatment uses two immune checkpoint inhibitors, durvalumab and tremelimumab. The two drugs[…]

Read More »

Gavo-Cel Moving to Phase II Trial for Mesothelioma

A study looking at T-cell therapy for mesothelioma is going to phase II of the clinical trial process. Researchers are trying to find out how effective the treatment is when combined with an approved immunotherapy combination. Researchers are looking at the relationship between gavocabtagene autoleucel (gavo-cel) with the combination of[…]

Read More »

Enzyme and Chemotherapy Combination for Mesothelioma

Pleural mesothelioma sufferers could improve their survival by as much as 30 percent when treated with the latest cancer enzyme and chemotherapy. In a recent study known as ATOMIC Meso, ADI-PEG 20 showed effectiveness when used for sarcomatoid and biphasic mesothelioma, the two most resistive to treatment. The enzyme is[…]

Read More »

STAR-101 Could Make CAR T-Cell Therapy More Effective for Mesothelioma Patients

Early next year, a new clinical trial will be conducted to test an immunotherapy treatment that has a new and unique delivery system. The study will be conducted at the University of Pennsylvania. The Food and Drug Administration gave orphan drug status to SynKIR-110, a CAR T-cell therapy utilized for[…]

Read More »

Allocetra and Cisplatin Combination for Mesothelioma

A new immunotherapy treatment is showing promising results against mesothelioma. The therapy consists of a combination of two drugs: one drug that reprograms macrophages and the other is the chemotherapy cisplatin. Mesothelioma is a cancer that does not respond well to treatment. The best option for patients is a combination[…]

Read More »

Drug Factories Treatment Being Tested for Mesothelioma

Researchers have found a treatment that can eradicate advanced stage mesothelioma tumors within a few days. The research is being done at Rice University and Baylor College of Medicine. The treatment utilizes implants known as “drug factories” and a checkpoint inhibitor drug. Mesothelioma is a tough to treat cancer of[…]

Read More »

Keytruda as a Second Line Treatment for Mesothelioma

A new second line treatment has been developed for pleural mesothelioma. The treatment was created at the Netherlands Cancer Institute in Amsterdam. Research was done as a single-arm, open-label clinical trial combining pembrolizumab (Keytruda) and lenvatinib. The results were presented at the IASCL 2022 World Conference on Lung Cancer in[…]

Read More »